Drug Profile
Research programme: anti-cancer biosimilars - Polpharma Biologics
Alternative Names: JNJ-6892Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Bioceros
- Developer Johnson & Johnson Innovative Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 13 Jul 2020 Polpharma Biologics acquired Bioceros and changed name to Polpharma Biologics